PROCESSA PHARMA Revenue, Profits - PCSA Quarterly Income Statement

Add to My Stocks
$3.3 $0.3 (10%) PCSA stock closing price Sep 17, 2018 (Closing)

PCSA stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the PROCESSA PHARMA stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2018 Q2 impacts the PCSA stock. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses as shown in the PROCESSA PHARMA profit and loss statement for 2018 Q2 total to $1.08M. This line item shows that the operating expenses has increased compared with last year. Also check: PROCESSA PHARMA assets and PROCESSA PHARMA free cash flow.

View and download details of revenue and profits for PROCESSA PHARMA for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
PROCESSA PHARMA Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
PROCESSA PHARMA Gross Profit
----------
Research & Development Expense1.08M---------
Selling General & Admin Expense-----0.02M----0.02M-
Income Before Depreciation Depletion Amortization-1.43M-1.29M-1.43M-0.16M--0.23M----0.07M
Depreciation Depletion Amortization----------
Non Operating Income-------0.02M---
Interest Expense---0.05M-------
PROCESSA PHARMA Pretax Income
-1.48M-1.37M-1.38M-0.2M-0.04M-0.23M-0.1M-0.06M-0.04M-0.13M
Provision for Income Taxes-0.28M-0.28M--------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-1.21M-1.1M-0.63M-0.2M-0.04M-0.23M-0.1M-0.07M-0.05M-0.13M
Extraordinary Items & Discontinued Operations----------
PROCESSA PHARMA Profit/ Loss (Net Income)
-1.21M-1.1M-0.63M-0.2M-0.04M-0.23M-0.1M-0.07M-0.04M-0.13M
Average Shares used to compute Diluted EPS36.62M35.27M35.12M1.59M---1.57M1.57M1.57M
Average Shares used to compute Basic EPS36.62M35.27M35.12M1.59M---1.57M1.57M1.57M
Income Before Nonrecurring Items-1.21M-1.1M-0.63M-0.2M----0.07M-0.07M-0.13M
Income from Nonrecurring Items----------
PROCESSA PHARMA Earnings Per Share Basic Net
-0.03-0.03-0.02-0.14----0.07-0.07-0.07
PROCESSA PHARMA Earnings Per Share Diluted Net
-0.03-0.03-0.02-0.14----0.07-0.07-0.07
EPS Diluted Before Nonrecurring Items-0.03-0.03-0.02-0.14----0.07-0.07-0.07
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on PROCESSA PHARMA stock analysis. It helps to look at the following income statement items:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this quarter of 2018 Q2. Our PROCESSA PHARMA revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. PCSA stock had a poor bottom line growth.

The income statement is also called statement of revenue and expense. The PCSA financials along with PROCESSA PHARMA historical stock prices provide a lot of details about the firm.

PROCESSA PHARMA Income Statement - Key Financial Ratios

Operating Margin
0
Net Profit Margin
0